Skip to main content
ABION Inc. logo

ABION Inc. — Investor Relations & Filings

Ticker · 203400 ISIN · KR7203400007 KO Professional, scientific and technical activities
Open in API
Filings indexed 409 across all filing types
Latest filing 2022-07-06 Regulatory Filings
Country KR South Korea
Listing KO 203400

About ABION Inc.

https://abionbio.com/en/

ABION Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative medicines, focusing on first-in-class and best-in-class therapeutics for oncology and viral diseases. The company's lead oncology asset is ABN401, a selective c-Met tyrosine kinase inhibitor (TKI) designed to treat non-small cell lung cancer (NSCLC) with MET mutations, which has shown a favorable safety profile. Another key pipeline candidate is ABN501, a novel monoclonal antibody targeting Claudin-3 for various cancers. Beyond oncology, ABION is developing ABN101, a second-generation Interferon-β formulated as a broad-spectrum anti-viral inhaler for respiratory infections. The company aims to commercialize its assets in global markets through internationally recognized clinical processes.

Recent filings

Filing Released Lang Actions
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory notice regarding the setting of a record date and shareholder register closure for an upcoming Extraordinary General Meeting (EGM). It does not contain the full proxy materials or the meeting presentation itself, but rather serves as a formal regulatory announcement of the administrative steps taken by the company. Given it is a standard regulatory disclosure regarding corporate actions, it fits best under the RNS category.
2022-07-06 Korean
투자판단관련주요경영사항(표적항암제 ABN401의 한국/호주 제1-2상 임상시험 결과)
Legal Proceedings Report Classification · 100% confidence The document is a regulatory filing from the Korean Exchange (KRX) system, specifically a 'Major Management Matter' disclosure regarding the results of a Phase 1-2 clinical trial for a drug (ABN401). It details the trial methodology, safety results, and future development plans. Since it is a formal regulatory disclosure of material information regarding company operations and clinical progress, it falls under the 'Regulatory Filings' category.
2022-05-17 Korean
분기보고서 (2022.03)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for the company '에이비온(주)' (Abion Inc.) covering the period from 2022.01.01 to 2022.03.31. It contains detailed financial information, business operations, capital structure, and management discussions, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2022
2022-05-13 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard regulatory filing in South Korea (DART system) used when an executive or major shareholder changes their ownership stake in the company. This falls under the category of 'Director's Dealing' (DIRS), which covers insider transactions and changes in ownership status by company insiders.
2022-04-27 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard regulatory filing in South Korea (DART system) used by corporate insiders to disclose changes in their shareholdings. This corresponds to the 'Director's Dealing' category, which covers insider trades and changes in ownership by company directors and executives.
2022-04-13 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service (FSS) and Korea Exchange. This is a standard regulatory filing used to disclose insider trading or changes in share ownership by company directors and executives. Based on the provided definitions, this falls under 'Director's Dealing' (DIRS).
2022-04-13 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.